Joel B. Braunstein, MD, MBA

Co-Founder, President and CEO

Dr. Braunstein is a board-certified cardiologist and internist, and has been CEO of C2N Diagnostics since its inception. Dr. Braunstein has co-founded and played a senior executive role in numerous emerging life sciences companies. He is a Founder and Managing Director of LifeTech Research (LTR) since 2004. Beside C2N and LTR, he currently serves as a corporate director at Tivorsan Pharmaceuticals, NexGen Medical Systems, and Correx. Dr. Braunstein received his M.D. with highest distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School until 1999, and as a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an MBA with management focus in 2004 and maintained an Assistant Professor cardiology faculty position at Johns Hopkins University. He remains an advisor to the Johns Hopkins Carey School of Business and serves on the Commercial Advisory Board for University of Maryland Ventures. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University.

Micah Onixt, JD, MBA

Company Secretary

Mr. Onixt is currently General Counsel and a Managing Director of LTR. Through LTR, he brings to C2N over 20 years of life sciences work experience. He was part of the team that helped to form C2N and to transfer the SILK-related intellectual property out of WU. He also was a partner in the Chicago office of the law firm of DLA LLP US and a recipient of the “40 Illinois Attorneys Under 40 to Watch” award from the Law Bulletin Publishing Company. During his 12 year tenure at DLA Piper, his practice consisted of representing both institutional investment funds, and private and public life sciences companies in the areas of corporate securities, technology transfer (product licensing, M&A), and intellectual property management. He has negotiated many partnerships; and drafted and prosecuted patents, copyrights, and trade secrets within the biotechnology, pharmaceutical and medical device spaces. Mr. Onixt received his MBA from the Northwestern University Kellogg School of Management in 2007, JD from Loyola University in 1998, a MS in Biology from the Illinois Institute of Technology in 2017, and two bachelor’s degrees from the University of Michigan (English, ‘94) and University of Illinois at Chicago (Cellular Biology, ‘95). 

Kevin Yarasheski, PhD

Senior Vice President

Dr. Yarasheski obtained the PhD in physiology from Kent State University and completed a three-year post-doctoral research fellowship in geriatrics, metabolism and endocrinology at Washington University School of Medicine. For 29+ years, Dr. Yarasheski remained in the Department of Internal Medicine at Washington University School of Medicine where he rose to the rank of tenured Full Professor, co-Directed the Biomedical Mass Spectrometry Research Facility, fully supported his independent mass spectrometry-based clinical research program, and collaborated with Drs. Bateman, West and Holtzman on their Alzheimer's disease projects that required mass spectrometry analysis. Dr. Yarasheski also conducted translational clinical research focused on using gas or liquid chromatography-mass spectrometry to detect, characterize and quantify biomolecules present in human biofluids and tissues, and that revealed underlying alterations in protein and amino acid metabolism that contributed to the pathogenesis of several conditions: unsuccessful aging, cachexia, malnutrition, and cardiometabolic complications. In 2016, Dr. Yarasheski joined C2N Diagnostics as Senior Vice President where he directs and supervises laboratory personnel and mass spectrometry research, development and discovery efforts focused on biomarkers for neurodegeneration and AD pathology.

Tim West, PhD

VP, Research and Development

Dr. West obtained his PhD in molecular cell biology and neuroscience from Washington University. He conducted his graduate thesis research and post-doctoral training in the laboratory of Dr. David Holtzman, one of C2N’s scientific founders. In those capacities, Dr. West led a group of scientists and technicians studying neonatal stroke and hypoxic-ischemic injury. During 2006 and 2007, he served as Staff Scientist and Assistant Director of Technology Development for the Hope Center for Neurological Disorders at the Washington University School of Medicine. Dr. West has extensive experience in database management and computer programming, and supports C2N’s establishment of a software platform tracking work flow and inventories, stores data, and enhances quality control. Dr. West was a recipient of a Kauffman Fellowship for Bio-Entrepreneurship. He received his B.Sc. Honors in Molecular Biology at University College London and performed a laboratory internship at the Ludwig Institute for Cancer Research.

Ilana Fogelman, MD, MPH

VP, Regulatory and Clinical Affairs

Dr. Fogelman co-founded LTR with Dr. Braunstein in 2004 and through LTR was involved in the formation of C2N Diagnostics. She specializes in corporate and product pipeline valuation, drug development, clinical trial design and analysis, and FDA regulations. Dr. Fogelman is an expert in regulatory strategies and risk, and interpreting FDA actions, decisions, and requirements. From 1999 to 2003, Dr. Fogelman worked as a biotechnology analyst for Merrill Lynch and Salomon Smith Barney, covering small- to mid-cap public companies. From 1993 to 1999, Dr. Fogelman worked as a medical reviewer for FDA's Center for Biologics Evaluation and Research, focusing on new products for infectious diseases, autoimmune and inflammatory disorders. In that position, she reviewed more than 80 INDs, 2 BLAs, and 2 BLA supplements for a variety of technologies, including monoclonal antibodies, cytokines, immunomodulators, cell and gene therapies, and vaccine therapies. While at the FDA, Dr. Fogelman was also the Principal Investigator of an HIV clinical trial, which she designed and implemented in collaboration with the NIH to evaluate the immunologic reconstitution of HIV-infected patients receiving highly active antiretroviral therapies. Dr. Fogelman obtained her M.D. from the University of São Paulo (Brazil) and a Master in Public Health from Harvard University. At Harvard, she also completed two postdoctoral research fellowships in HIV clinical trials and immunology.

Yan Helen Hu, Ph.D.

Director of Technologies and Business Development

Dr. Hu  brings to C2N unique expertise in bioanalytical technologies, biomarker and antibody therapeutics discovery and development. Dr. Hu obtained her PhD in Molecular Genetics from Washington University. Following graduation, she worked with Dr. David Holtzman, one of C2N’s scientific founders, under the Ruth L. Kirschstein postdoctoral fellowship. In that position, she employed a comparative proteomics approach and discovered novel biomarkers for early stage Alzheimer’s Disease. Dr. Hu subsequently worked in the pre-clinical group at Genentech, Inc., where she successfully led the anti-interleukin 17 program from late stage research to preclinical development and played a key role in preparation of an IND filing. At C2N, Dr. Hu has led the efforts in bioanalytical support of preclinical and early clinical development of ABBV-8E12 program. She currently leads the development of diagnostics for neurodegenerative diseases, focusing on building strategic partnerships and business relationships.

Philip Verghese, PhD

Director, Research, Development, and Operations

Dr. Verghese is a protein and lipid biochemist with extensive experience in acute and chronic neurodegenerative disease models. He conducted his post-doctoral training in the laboratory of Dr. David Holtzman, one of C2N’s scientific founders, under the BrightFocus foundation postdoctoral research fellowship. His work on apolipoprotein E (apoE) (for Alzheimer’s disease) and nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) (for acute neurodegeneration in the developing brain) has been published in high impact journals and added new perspectives in the field of neurodegeneration. Dr. Verghese’s graduate work was focused on peripheral lipid metabolism. He also holds a Graduate Diploma in Business Studies from Dublin Business School, Dublin, Ireland.

Matthew Meyer, PhD

Senior Proteomics Scientist

Dr. Meyer is a protein biochemist with broad expertise in the field of proteomics including mass spectrometry-based protein biomarker discovery, identification of post-translational modifications, and targeted, quantitative assay development. During his postdoctoral training from 2012-15 at Washington University in St. Louis, School of Medicine, Dr. Meyer focused on translational research establishing mass spectrometry workflows for quantitative, multiplexed assays as part of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). While completing his time at Washington University, he successfully developed novel strategies for the enrichment and quantification of over 200 kinases in the human breast cancer kinome. His graduate thesis work included understanding the activation of protein receptor kinases via phosphorylation site mapping and biophysical characterization of kinase domain interfaces using hydrogen-deuterium exchange MS. He received his BS in Biochemistry from the University of Missouri-Columbia and his PhD in Biochemistry from Iowa State University.

Kristopher Kirmess, PhD

Bioanalytical Chemist

Dr. Kirmess is an analytical chemist with a vast knowledge of chromatographic separations and mass spectrometry. Dr. Kirmess obtained his PhD in analytical chemistry from Southern Illinois University at Carbondale while investigating primary ion formation mechanisms within matrix assisted laser desorption/ionization. Dr. Kirmess conducted his post-doctoral training at Washington University School of Medicine in Dr. Kevin Yarasheski’s lab where he conducted assay development on liquid chromatography tandem mass spectrometry for comparative metabolomics. At C2N Diagnostics, Dr. Kirmess applies state-of-the art mass spectrometry techniques to advance both basic and applied knowledge towards identifying, characterizing, and quantifying biomolecules that inform us about disease mechanisms, and can serve as diagnostic or theragnostic biomarkers.

Erin Smith, BS

Laboratory and Quality Assurance Manager

Ms. Smith’s role at C2N includes supervision of the laboratory, shipping and quality assurance manager at C2N. Her role includes supervision of the laboratory, shipping and receiving, creation and revision of standard operating procedures, quality auditing, and document control. Prior to joining C2N, Ms. Smith spent over a decade co-managing a small animal imaging facility conducting collaborative research with investigators at Washington University School of Medicine.

Scott Harpstrite, MS

Laboratory and Quality Control Manager

Mr. Harpstrite is a laboratory manager with experience in biotech and academic research. He received an MS in chemistry from SIUE in 2002. In 14+ years at Washington University School of Medicine, he transitioned from chemical synthesis and characterization to in vitro and in vivo evaluation of preclinical agents, project leadership, and laboratory management. Mr. Harpstrite joined C2N in 2015, his role includes quality control, oversight of safety and compliance, shipping and receiving, and development and implementation of SOPs.

Mary Holubasch, M.T., ASCP

Senior Clinical Lab Scientist

Mary came to C2N in 2008 with over 15 years of experience in CLIA laboratories in both small esoteric hospital settings and high-throughput labs. She obtained her BS in Biology at SIUE and her American Society for Clinical Pathology (ASCP) board certification in laboratory science through the Mercy School of Medical Technology. She is proficient in all areas of laboratory operations from analysis with manual and automated techniques through documentation and reporting with adherence  to CLIA standards.